Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)-Reference-Cited by-同舟云学术

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)

Published:2013-10 Issue:1 Volume:82 Page:115-120
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Reaume M. Neil,Leighl Natasha B.,Mittmann Nicole,Coyle Doug,Hirsh Vera,Seymour Lesley,Tu Dongsheng,Shepherd Frances A.,Graham Barbara,Gridelli Cesare,Perrone Francesco,Di Maio Massimo,Bradbury Penelope A.,Evans William K.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2012, Toronto, Canada; 2012.

2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

3. Significantly higher survival with Gemcitabine-cisplatin vs. cisplatin in advanced non-small cell lung cancer (NSCLC): final results from an international phase III study;Sandler,1998

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group;Non-small Cell Lung Cancer Collaborative G.;Br Med J,1995

5. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients;Le Chevalier;J. Clin. Oncol.,1994

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access;American Society of Clinical Oncology Educational Book;2021-06

2. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada;Lung Cancer;2018-11

3. RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine;OncoTargets and Therapy;2018-09

4. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature;PharmacoEconomics;2017-08-31

5. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada;Journal of Medical Economics;2016-03-02